Jubilant Ingrevia Limited has released the transcript of its investors' conference call for the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The company reported its highest quarterly revenue in 14 quarters at ₹1,179 crore, a 12% year-on-year increase, driven by 10% volume growth. EBITDA stood at ₹172 crore, up 11% year-on-year, while PAT was ₹86 crore, rising 17% year-on-year. The Board has recommended a final dividend of ₹2.5 per share, taking the total FY26 dividend to ₹5 per share.

The disclosure was submitted to BSE Limited and the National Stock Exchange of India Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The submission was made by Deepanjali Gulati, Company Secretary of Jubilant Ingrevia .

Financial Performance

Management highlighted that Specialty Chemicals achieved its best quarterly revenue at ₹516 crore, with EBITDA margins maintained at 27% for the last six quarters. The Nutrition business reported segment revenue of ₹230 crore, up 21% year-on-year, with segment EBITDA growing 42% quarter-on-quarter. The company's net debt-to-EBITDA ratio improved to 0.99x.

Strategic Updates

Jubilant Ingrevia noted effective handling of the Middle East crisis with no production loss. The company completed the acquisition of Remidex Pharma to accelerate its Human Nutrition business and successfully commissioned the Bharuch CDMO plant. Management expects sequential growth in revenue and EBITDA starting from Q1 FY27, driven by Specialty Chemicals and Nutrition.

Key Details

The transcript can be accessed via the link provided on the company's website.

Jubilant Ingrevia Limited reported a consolidated net profit of ₹277.91 crore for the financial year ended March 31, 2026, an increase of 10.6% from ₹251.17 crore in the previous year. Revenue from operations for FY26 stood at ₹4388 crore, compared to ₹4177.61 crore in FY25. The Board of Directors, at its meeting held on May 26, 2026, approved the audited financial results and recommended a final dividend of ₹2.5 per equity share, amounting to ₹39.82 crore, subject to shareholder approval. This takes the total dividend for FY26 to ₹5 per share. The company has outlined a long-term growth strategy targeting 3X revenue and 4X EBITDA by FY30.

Financial Performance for FY26

The audited financial results for the year ended March 31, 2026, reflect growth in both top-line and bottom-line figures. The following table summarises the key financial metrics for the consolidated financial results:

Quarterly and Operational Highlights

For the quarter ended March 31, 2026 (Q4FY26), the company reported a consolidated net profit of ₹86.44 crore, up from ₹74.05 crore in the same quarter of the previous year. Revenue for Q4FY26 was ₹117.87 crore, compared to ₹105.13 crore in Q4FY25. EBITDA for the quarter stood at ₹16.30 crore, with a margin of 13.8%. The company's operating margin for the year was 8.92%, while the net profit margin was 6.28%.

Strategic Developments and Dividend

During the year, the company acquired a 100% stake in Remidex Pharma Private Limited for ₹16.28 crore to expand its presence in human nutrition and pharmaceutical manufacturing. The Board approved the audited financial results, which received an unmodified opinion from the statutory auditors, Walker Chandiok & Co LLP. The total dividend for FY26, including the interim dividend already paid, amounts to ₹5 per equity share.

Debt Position

As of March 31, 2026, the company's total gross debt stood at ₹777 crore, comprising long-term borrowings of ₹446 crore and short-term borrowings of ₹332 crore. Cash and equivalents were reported at ₹190 crore, resulting in a total net debt of ₹587 crore, representing a year-on-year decrease of 11%.

CDMO Pipeline and Growth Outlook

Jubilant Ingrevia has outlined a robust CDMO (Contract Development and Manufacturing Organisation) growth strategy, with strong volume growth recorded across various businesses, including new molecules. The company has identified over 100 opportunities worth INR 3,500 crore, with more than 20 confirmed molecules and 10+ molecules in advanced stages carrying a peak potential of INR 1,100 crore. The following table captures the key highlights of the CDMO pipeline and strategic targets:

New CDMO opportunities are forecasted to add 20%-25% of peak revenue in the first year, 50%-60% in the second year, and more than 80% by the third year. The company expects revenue and EBITDA to increase sequentially in Q1 FY27 and the following quarters, driven by growth in Specialty Chemicals, Nutrition, and Acetyls for the full FY27. Jubilant Ingrevia aims for at least 20% yearly EBITDA growth and projects capital expenditure of INR 400 to INR 500 crore for FY27, in line with its previous growth plans. The company's long-term ambition targets annual revenue growth of 20% to 25% with steady pricing.